Advertisement

Topics

Companies Related to "Syros Announces Preclinical Data 1365 Showing Potent Anti" [Most Relevant Company Matches] RSS

22:28 EDT 19th October 2018 | BioPortfolio

Here are the most relevant search results for "Syros Announces Preclinical Data 1365 Showing Potent Anti" found in our extensive corporate database of over 50,000 company records.

Showing "Syros Announces Preclinical Data 1365 Showing Potent Anti" Companies 1–25 of 3,400+

Extremely Relevant

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel ...


Syros Pharmaceuticals

Syros Pharmaceuticals is a life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros’ proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics. Syros’ initial focus is in cancer, but the company platform will al...

Relevant

Synergys Biotherapeutics

Synergys is an early stage company developing multifunctional anti-vascularization antibody drugs targeting VEGF-alternative pathways. The Company’s most advanced product candidate, Anti-EGFR‐TAP (SYN001) was derived from its platform technology termed A‐TAP (Antibody-Targeted Anti-Vascularization Payload). SYN001 is currently in preclinical ...


Axentis Pharma AG

Axentis Pharma is a Swiss-based pharmaceutical company focused on chronic lung diseases and respiratory related disorders, especially on cystic fibrosis. Axentis Pharma is solely financed by private investors. The company is currently looking for co-development and co-marketing partners in the respiratory arena with the goal to create a competence center for healthcare professionals and patients...

Intezyne

Intezyne is dedicated to treating cancer better by offering a new solution to oncologists, who must balance the anti-tumor activity of best-in-class chemotherapeutics with their severe toxicities. Drawing from their expertise in polymer chemistry, the Company’s founders created the IVECT Method to limit chemotherapeutics’ anti-tumor activity to w...

ImQuest Life Sciences, Inc.

ImQuest BioSciences, a privately held U.S. company located in Frederick, Maryland is a leading provider of anti-infective therapeutic and microbicide development and anti-cancer services to the biotechnology and pharmaceutical industry. ImQuest has broad based capabilities to assist companies with the discovery and preclinical development of new therapeutics, vaccines and preventatives, as well as...

Crown Bioscience, Inc.

Crown Bioscience, Inc. is a U.S.-based drug discovery service company with R&D facilities in China committed to advancing anti-cancer therapeutics through the preclinical and drug development stages. Its proprietary CrystalClearTM , HuPrime™ and HuKemia™ platforms enable unique lead optimization and translational oncology strategies to deliver ...

Algos Preclinical Services

Founded as Algos Therapeutics, Inc. in 2003, the company recently changed its corporate identity to Algos Preclinical Services to reflect its new strategic market positioning as a US-based preclinical, in vivo CRO that provides contract research services to pharmaceutical, biotech and medical device markets. Algos Preclinical supports the development of its customers' products from its facilities ...

External Pharma Inc

External Pharma, Inc. provides preclinical drug discovery and development support to pharmaceutical and biotech companies as fee for service or in collaboration with a partner. Our main focus is to evaluate drug candidates and targets for neurological and psychiatric indications. External Pharma represents the next generation of CROs - highly experienced drug development scientists working in a st...

InterMune Pharmaceuticals

InterMune, Inc., is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. We market Actimmune® (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. We have a late-stage and preclinical development pipeline in the areas of pulmonology and hepatology. In pulmono...

FLX Bio, Inc.

FLX475 is a best-in-class oral, small molecule antagonist of CCR4. CCR4 ligands are elevated in multiple tumor types when compared to normal tissue. In preclinical studies, FLX475 inhibited tumor growth and increased tumor regression. In addition, FLX475 enhanced the antitumor effects of various checkpoint inhibitors including anti-PD-L1 and anti-CTLA4 ant...

GT Biologics

GT Biologics is focused on the research and development of Live Biotherapeutics (LBPs) for the treatment of autoimmune diseases. GT Biologics aim to deliver a new class of medicine based on the potent immune-regulating properties of novel bacterial isolates derived from the healthy human gut. We have completed a research-intensive innovative programme spanning several years investigating the i...

Vestiage, Inc.

Vestiage (Pink Sheets: VEST) is a publicly traded anti-aging lifestyle company offering premium branded science-based cosmeceuticals and nutraceuticals. Vestiage is focused on the use of human stem cell, marine/ocean, and cutting edge botanically based science and ingredients to produce highly potent, elegantly formulated products with clinically proven...

ProtoKinetix, Incorporated

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases t...

Vascular Biogenics Ltd.

Vascular Biogenics Ltd. (VBL) is a biopharmaceutical company focused on developing novel treatments for pathologies in which vascular biology plays a critical role. Based on its leading research expertise in vascular biology VBL has developed lead candidates in the fields of cardiovascular health and solid tumor cancer treatment.Cardiovascular Health: Attacking Atherosclerosis through Anti-Inflamm...

Cellgate, Inc

Cellgate is rapidly advancing a portfolio of novel anti-proliferation therapeutics that has the potential to provide patients with new treatment options. We currently have two programs progressing through clinical development as well as several oncology programs undergoing preclinical evaluation.

NuMedii, Inc.

NuMedii discovers and de-risks effective new drugs by translating its predictive Big Data technology into therapies with a higher probability of therapeutic success.  The company’s Big Data technology, originally developed at Stanford and licensed exclusively to NuMedii, consists of billions of data points of ever-increasing amounts of comprehensive ...

BioDiem Ltd

BioDiem has acquired its initial products from leading Russian medical research institutes. This alliance has provided BioDiem with access to research projects with advanced data, in three cases with clinical studies showing promising results. To effectively manage development costs, BioDiem out-sources its research and development requirements to appropriate institutional centres of excellence an...

Collaborative Drug Discovery, Inc.

Collaborative Drug Discovery, Inc. (CDD) -- http://www.collaborativedrug.com -- provides web-based software that organizes preclinical research data to help scientists advance new drug candidates more effectively. The CDD database enables scientists to "archive, mine, and collaborate"(R) around preclinical chemical and biological drug discovery data through a web-based interface. The software ...

Algomedix Inc.

Algomedix Inc., a biotech company located in Mill Creek WA, and San Diego, CA, is developing potential first-in-class non-opioid medicines for chronic and acute pain. The company’s patented TRPA1 modulators, which are small molecule, orally delivered compounds, are designed to provide effective pain relief without any potential for addiction or abuse....

Barricade Therapeutics, Corp.

Barricade Therapeutics, Corp. (www.barricadetherapeutics.com) is a privately-held Biotech company based in Houston, TX. Barricade was founded based on discovery and advancement of novel first-in-class anti-cancer small molecules. The current status of the development programs is preclinical.

nano tech 2013

(1) A growing number of exhibits showing practical nanotech applications and actual products

ADC Therapeutics

ADC Therapeutics sarl (ADCT) is a Swiss-based oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers such as breast lung, prostate, renal and blood. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to particular types of ...

Zymeworks Inc.

Zymeworks is a privately held biotechnology company that is developing best-in-class antibody therapeutics for the treatment of oncology, autoimmunity and inflammatory diseases. The company’s proprietary ZymeCAD™ structure-guided protein engineering technology and its novel Azymetric™ and AlbuCORE™ platforms enable the development of highly ...

BitBite

BitBite is the first wearable device that uses an Automatic Dietary Recording System (ADRS) to monitor and improve how you eat. BitBite is a revolutionary patent-pending, modern-designed, ultra-comfort ear piece that monitors the users eating pace, quantity, frequency and location. It aggregates information using real-time data analysis and pattern recogni...


More From BioPortfolio on "Syros Announces Preclinical Data 1365 Showing Potent Anti"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks